CO2018000431A2 - Compuesto de imidazodiazepina - Google Patents
Compuesto de imidazodiazepinaInfo
- Publication number
- CO2018000431A2 CO2018000431A2 CONC2018/0000431A CO2018000431A CO2018000431A2 CO 2018000431 A2 CO2018000431 A2 CO 2018000431A2 CO 2018000431 A CO2018000431 A CO 2018000431A CO 2018000431 A2 CO2018000431 A2 CO 2018000431A2
- Authority
- CO
- Colombia
- Prior art keywords
- disease
- compound
- dopamine
- receptor
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se provee un compuesto el cual es útil como un modulador alostérico positivo del receptor de dopamina D1 (D1 MAP). Los presentes inventores han estudiado un compuesto el cual tiene un efecto modulador alostérico positivo (efecto MAP) sobre un receptor de dopamina D1 y el cual puede utilizarse como un ingrediente activo de una composición farmacéutica para prevenir y/o tratar el deterioro cognitivo, el síntoma negativo de la esquizofrenia, CIAS, enfermedad de Parkinson, enfermedad de Alzheimer, enfermedad de Huntington, depresión, ADHD, drogodependencia, o trastornos similares. Por consiguiente, han descubierto que el compuesto de imidazodiazepina de la presente invención tiene un efecto MAP sobre un receptor de dopamina D1, y de ese modo completaron la presente invención. El compuesto de imidazodiazepina de la presente invención tiene un efecto MAP sobre un receptor de dopamina D1, y se prevé que sea un agente para prevenir y/o tratar el deterioro cognitivo, el síntoma negativo de la esquizofrenia, CIAS, la enfermedad de Parkinson, la enfermedad de Alzheimer, la enfermedad de Huntington, la depresión, ADHD, la drogodependencia, o trastornos similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015123478 | 2015-06-19 | ||
| PCT/JP2016/068080 WO2016204268A1 (ja) | 2015-06-19 | 2016-06-17 | イミダゾジアゼピン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018000431A2 true CO2018000431A2 (es) | 2018-04-10 |
Family
ID=57546103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0000431A CO2018000431A2 (es) | 2015-06-19 | 2018-01-17 | Compuesto de imidazodiazepina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10426784B2 (es) |
| EP (1) | EP3312181B1 (es) |
| JP (1) | JP6658753B2 (es) |
| KR (1) | KR102591169B1 (es) |
| CN (2) | CN107635996B (es) |
| AR (1) | AR105025A1 (es) |
| AU (1) | AU2016279518B2 (es) |
| CA (1) | CA2989982C (es) |
| CO (1) | CO2018000431A2 (es) |
| CY (1) | CY1122232T1 (es) |
| DK (1) | DK3312181T3 (es) |
| ES (1) | ES2751913T3 (es) |
| HR (1) | HRP20191961T1 (es) |
| HU (1) | HUE047430T2 (es) |
| IL (1) | IL256252B (es) |
| LT (1) | LT3312181T (es) |
| MX (1) | MX2017016690A (es) |
| MY (1) | MY197499A (es) |
| PH (1) | PH12017502253A1 (es) |
| PL (1) | PL3312181T3 (es) |
| PT (1) | PT3312181T (es) |
| RS (1) | RS59497B1 (es) |
| RU (1) | RU2712968C2 (es) |
| SG (1) | SG11201710345VA (es) |
| SI (1) | SI3312181T1 (es) |
| TW (1) | TWI697496B (es) |
| UA (1) | UA120006C2 (es) |
| WO (1) | WO2016204268A1 (es) |
| ZA (1) | ZA201708566B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
| WO2004000837A1 (ja) * | 2002-06-25 | 2003-12-31 | Sumitomo Pharmaceuticals Co., Ltd. | 新規なベンズオキサゾリノン誘導体 |
| WO2005080335A1 (en) * | 2004-02-13 | 2005-09-01 | President And Fellows Of Harvard College | 3-3-di-substituted-oxindoles as inhibitors of translation initiation |
| WO2005080334A1 (ja) * | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 新規へテロ環化合物 |
| EP1756071B1 (en) | 2004-05-27 | 2009-08-26 | UCB Pharma S.A. | Benzoxazolone derivatives, processes for preparing them and their uses |
| CL2007002097A1 (es) | 2006-07-20 | 2008-01-18 | Smithkline Beecham Corp | Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras. |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| UY33463A (es) * | 2010-06-24 | 2012-01-31 | Takeda Pharmaceutical | Compuestos heterocíclicos fusionados |
| AR095883A1 (es) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
-
2016
- 2016-06-16 AR ARP160101804A patent/AR105025A1/es unknown
- 2016-06-17 WO PCT/JP2016/068080 patent/WO2016204268A1/ja active Application Filing
- 2016-06-17 DK DK16811742T patent/DK3312181T3/da active
- 2016-06-17 KR KR1020177036276A patent/KR102591169B1/ko active IP Right Grant
- 2016-06-17 MX MX2017016690A patent/MX2017016690A/es active IP Right Grant
- 2016-06-17 EP EP16811742.2A patent/EP3312181B1/en active Active
- 2016-06-17 SI SI201630411T patent/SI3312181T1/sl unknown
- 2016-06-17 AU AU2016279518A patent/AU2016279518B2/en active Active
- 2016-06-17 TW TW105119205A patent/TWI697496B/zh not_active IP Right Cessation
- 2016-06-17 HU HUE16811742A patent/HUE047430T2/hu unknown
- 2016-06-17 ES ES16811742T patent/ES2751913T3/es active Active
- 2016-06-17 PL PL16811742T patent/PL3312181T3/pl unknown
- 2016-06-17 PT PT168117422T patent/PT3312181T/pt unknown
- 2016-06-17 CA CA2989982A patent/CA2989982C/en active Active
- 2016-06-17 UA UAA201800508A patent/UA120006C2/uk unknown
- 2016-06-17 LT LTEP16811742.2T patent/LT3312181T/lt unknown
- 2016-06-17 CN CN201680034335.2A patent/CN107635996B/zh active Active
- 2016-06-17 MY MYPI2017704807A patent/MY197499A/en unknown
- 2016-06-17 CN CN202010083916.3A patent/CN111205292B/zh active Active
- 2016-06-17 JP JP2017524854A patent/JP6658753B2/ja active Active
- 2016-06-17 RS RS20191427A patent/RS59497B1/sr unknown
- 2016-06-17 RU RU2018101861A patent/RU2712968C2/ru active
- 2016-06-17 US US15/737,564 patent/US10426784B2/en active Active
- 2016-06-17 SG SG11201710345VA patent/SG11201710345VA/en unknown
-
2017
- 2017-12-11 IL IL256252A patent/IL256252B/en active IP Right Grant
- 2017-12-11 PH PH12017502253A patent/PH12017502253A1/en unknown
- 2017-12-15 ZA ZA2017/08566A patent/ZA201708566B/en unknown
-
2018
- 2018-01-17 CO CONC2018/0000431A patent/CO2018000431A2/es unknown
-
2019
- 2019-10-16 CY CY20191101083T patent/CY1122232T1/el unknown
- 2019-10-30 HR HRP20191961TT patent/HRP20191961T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
| DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
| CL2017001718A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2017003127A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico. | |
| AR102657A1 (es) | Composición para tratar telas | |
| GT201500293A (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso | |
| CL2018002335A1 (es) | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 | |
| BR102015017380A2 (pt) | dispositivo para a reticulação do tecido do olho, e, composição farmacêutica | |
| CR20160433A (es) | Nuevos compuestos | |
| SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
| CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
| CL2015002817A1 (es) | Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). | |
| CR20150299A (es) | Dispersión sólida de un modulador selectivo de los receptores de progesterona | |
| BR112015026512A2 (pt) | composto acetamida heterocíclico | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| CO2018000431A2 (es) | Compuesto de imidazodiazepina | |
| CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
| CL2017001680A1 (es) | Composición farmacéutica para el tratamiento de enfermedades gastrointestinales | |
| SV2017005527A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
| BR112016029417A2 (pt) | desmopressina estabilizada | |
| CO2018002472A2 (es) | Compuesto de tetrahidrooxepinopiridina | |
| ECSP19040732A (es) | Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina | |
| CL2019001462A1 (es) | Composición mejorada de lansoprazol y simeticona y proceso para prepararla. | |
| TH183160A (th) | สารประกอบเฮตเทอโรไซคลิค อะซีทาไมด์ |